Nephros, Inc. (NEPH)
NASDAQ: NEPH · Real-Time Price · USD
2.790
-0.300 (-9.71%)
At close: Nov 6, 2026, 4:00 PM EST
2.800
+0.010 (0.36%)
After-hours: Nov 6, 2026, 7:30 PM EST
Nephros Revenue
Nephros had revenue of $5.62M in the quarter ending September 30, 2026, with 18.01% growth. This brings the company's total for the last twelve months to $21.58M, up 20.36% year-over-year. In the year 2025, Nephros had annual revenue of $18.79M with 32.67% growth. That makes Nephros the 33,390th largest company in the world by revenue and 4,378th in the United States.
Revenue (ttm)
$21.58M
Revenue Growth
+20.36%
P/S Ratio
1.40
Revenue / Employee
$599,444
Employees
36
Market Cap
30.30M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 18.79M | 4.63M | 32.67% |
| Dec 31, 2024 | 14.16M | -76.00K | -0.53% |
| Dec 31, 2023 | 14.24M | 4.26M | 42.74% |
| Dec 31, 2022 | 9.98M | -242.00K | -2.37% |
| Dec 31, 2021 | 10.22M | 1.66M | 19.34% |
| Dec 31, 2020 | 8.56M | -1.77M | -17.16% |
| Dec 31, 2019 | 10.33M | 4.65M | 81.71% |
| Dec 31, 2018 | 5.69M | 1.88M | 49.30% |
| Dec 31, 2017 | 3.81M | 1.49M | 64.18% |
| Dec 31, 2016 | 2.32M | 376.00K | 19.34% |
| Dec 31, 2015 | 1.94M | 196.00K | 11.21% |
| Dec 31, 2014 | 1.75M | 8.00K | 0.46% |
| Dec 31, 2013 | 1.74M | -67.00K | -3.71% |
| Dec 31, 2012 | 1.81M | -407.00K | -18.38% |
| Dec 31, 2011 | 2.21M | -724.00K | -24.64% |
| Dec 31, 2010 | 2.94M | 277.00K | 10.41% |
| Dec 31, 2009 | 2.66M | 1.19M | 80.65% |
| Dec 31, 2008 | 1.47M | 277.00K | 23.16% |
| Dec 31, 2007 | 1.20M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Harvard Bioscience | 87.81M |
| Retractable Technologies | 33.90M |
| Precision Optics Corporation | 31.53M |
| Bionano Genomics | 30.18M |
| Stereotaxis | 30.07M |
| Milestone Scientific | 9.42M |
| Femasys | 2.30M |
| Cuprina Holdings (Cayman) Limited | 38.79K |
NEPH News
- 2 days ago - Nephros price target lowered to $4.25 from $4.75 at Northland - TheFly
- 3 days ago - Nephros Earnings Call Transcript: Q3 2026 - Transcripts
- 3 days ago - Nephros Quarterly report: Q3 2026 - Filings
- 3 days ago - Nephros Earnings release: Q3 2026 - Filings
- 10 days ago - Nephros Schedules Third Quarter 2026 Financial Results Conference Call - GlobeNewsWire
- 25 days ago - Nephros Proxy statement: Proxy filing - Filings
- 3 months ago - Nephros reports Q2 EPS 11c, consensus 0c - TheFly
- 3 months ago - Nephros Earnings Call Transcript: Q2 2026 - Transcripts